- Home
- KEY vs PODD Comparison
KEY vs PODD Comparison
Compare KEY & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEY
- PODD
- Stock Information
- Founded
- KEY 1825
- PODD 2000
- Country
- KEY United States
- PODD United States
- Employees
- KEY N/A
- PODD N/A
- Industry
- KEY Major Banks
- PODD Medical/Dental Instruments
- Sector
- KEY Finance
- PODD Health Care
- Exchange
- KEY Nasdaq
- PODD Nasdaq
- Market Cap
- KEY 18.8B
- PODD 19.0B
- IPO Year
- KEY N/A
- PODD 2007
- Fundamental
- Price
- KEY $15.77
- PODD $258.75
- Analyst Decision
- KEY Buy
- PODD Buy
- Analyst Count
- KEY 20
- PODD 17
- Target Price
- KEY $19.15
- PODD $294.65
- AVG Volume (30 Days)
- KEY 16.4M
- PODD 880.6K
- Earning Date
- KEY 04-17-2025
- PODD 05-08-2025
- Dividend Yield
- KEY 5.19%
- PODD N/A
- EPS Growth
- KEY N/A
- PODD 96.55
- EPS
- KEY N/A
- PODD 5.78
- Revenue
- KEY $4,239,000,000.00
- PODD $2,071,600,000.00
- Revenue This Year
- KEY $75.54
- PODD $20.58
- Revenue Next Year
- KEY $7.23
- PODD $17.41
- P/E Ratio
- KEY N/A
- PODD $44.73
- Revenue Growth
- KEY N/A
- PODD 22.07
- 52 Week Low
- KEY $13.11
- PODD $160.19
- 52 Week High
- KEY $20.04
- PODD $289.46
- Technical
- Relative Strength Index (RSI)
- KEY 40.75
- PODD 44.69
- Support Level
- KEY $15.13
- PODD $258.25
- Resistance Level
- KEY $16.86
- PODD $276.13
- Average True Range (ATR)
- KEY 0.42
- PODD 8.60
- MACD
- KEY 0.09
- PODD 0.94
- Stochastic Oscillator
- KEY 45.23
- PODD 55.53
About KEY KeyCorp
With assets of over $180 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it world-wide.